CINGULATE INC. CING 深 滬
已收盤 09-19 16:00:00 美东时间
5.14
+0.200
+4.05%
華盛通- 最 高5.30
- 今 開4.97
- 成交量 28.23万股
- 最 低 4.92
- 昨 收 4.94
- 總市值 442.86万
- 52周最高 180.00
- 市盈率 靜 --
- 換手率 32.76%
- 52周最低 1.8001
- 委 比 96.48%
- 總股本 86.16万
- 歷史最高 1236.00
- 量 比 0.69
- 振 幅 7.69%
- 歷史最低 2.574
- 每 手 1
- 風險率 47.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Powerfleet Announces Strategic Acquisition of Fleet Complete
Expected to Create Industry Powerhouse with Total Revenue Anticipated to Exceed $400 Million Including $300+ Million of Recurring High Margin SaaS Revenue Highly Accretive with $200 Million ...
09-18 19:00
Assessing Fox Factory Hldg: Insights From 4 Financial Analysts
4 analysts have shared their evaluations of Fox Factory Hldg (NASDAQ:FOXF) duri...
09-13 05:00
STELLUS CAPITAL MANAGEMENT, LLC PROVIDES UNITRANCHE FINANCING IN SUPPORT OF DFW CAPITAL PARTNERS' INVESTMENT IN B&A
HOUSTON, Sept. 10, 2024 /PRNewswire/ -- Stellus Capital Management, LLC ("Stell...
09-10 18:00
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Theriva Biologics (AMEX:TOVX) shares moved upwards by 25.0% to $5.88 d...
09-03 00:30
国泰航空(00293.HK)向港交所申请25亿美元中期票据计划上市
久期财经讯，8月28日，国泰航空有限公司(CATHAY PACIFIC AIRWAYS LIMITED，简称“国泰航空”，00293.HK)发布公告表示，已向香...
08-29 09:20
How Is The Market Feeling About Cingulate?
Cingulate's (NYSE:CING) short percent of float has fallen 75.73% since its last...
08-27 22:45
Watching Cingulate; Zacks Small-Cap Research Gives stock $70 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_08262024_CING_Vandermosten.pdf
08-26 21:07
Cingulate files to sell 1M shares of common stock for holders
Cingulate (NASDAQ:CING) filed a prosptectus to sell 1M shares of common stock for holders. This preliminary prospectus is not an offer to sell. Filing More on Cingulate Seeking Alpha’s Quant Rating on...
08-20 00:08
Cingulate Shares Are Trading By More Than 200% Friday: What You Need To Know
Cingulate Inc. (NASDAQ: CING) shares are on an upward trajectory Friday. It follows the announcement that Cingulate has been granted European Patent No. 3261625 for its flagship asset, CTx-1301, which is designed to treat Attention Deficit Hyperactivity Disorder (ADHD).
08-17 02:59
